HGGA

Inside HGG Advances: A Chat with Tianyu Zhang

Posted By: HGG Advances HGGA: What motivated you to start working on this project? TZ: As a researcher with biostatistics training, I feel it is crucial to get my hands on real-world data to validate the efficiency of many methods that people develop on paper or whiteboards. My advisor kindly offered me this opportunity! HGGA:... Read More

Gautam Pandey, PhD is a postdoctoral fellow in the Department of Genetics at the University of North Carolina-Chapel Hill.

Inside HGG Advances: A Chat with Gautam Pandey

Posted By: HGG Advances HGGA: What motivated you to start working on this project? GP: Non-alcoholic fatty liver disease is a silent epidemic, and 25% of Americans are affected by it. There are currently not any medications approved for this disease. This is partly because we poorly understand the genetic mechanisms associated with this disease.... Read More

Cassie Spracklen, PhD is an assistant professor in the Department of Biostatistics and Epidemiology at the University of Massachusetts-Amherst.

Inside HGG Advances: A Chat with Cassie Spracklen

Posted By: HGG Advances HGGA: What motivated you to start working on this project? CS: In order to move from genome-wide associated loci toward potentially effective clinical and therapeutic targets, we need to identify which target/effector gene(s) the associate variants are being modulated. There are multiple methods that currently exist that can be used to... Read More

Inside <em>HGG Advances</em>: A Chat with Thales Nepomuceno

Inside HGG Advances: A Chat with Thales Nepomuceno

Posted By: HGG Advances HGGA: what motivated you to start working on this project? TN: I have been involved in several BRCA1-related projects and what has always driven me is the clinical consequences of identifying carriers of BRCA1 germline pathogenic variants. These individuals are at substantially higher risk of developing breast and ovarian cancer than... Read More

Nina Gold, MD is an attending physician in the Division of Medical Genetics and Metabolism at Massachusetts General Hospital.

Inside HGG Advances: A Chat with Nina Gold

Posted By: HGG Advances HGGA: What motivated you to start working on this project?  NG: Although monogenic genetic disorders are individually rare, collectively they affect up to 1 in 20 people in the global population. Over 700 monogenic disorders—including many inherited metabolic disorders, which I study and treat clinically—now have targeted treatments. As more therapies... Read More

ASHG uses cookies to provide you with a secure and custom web experience. Privacy Policy